Guidelines for Waiting Periods Between Imaging Procedures Performed Before MBI Examination
| Modality | Procedure | Administered dose | Recommended waiting period |
| CT | With or without contrast | None | |
| MRI | With or without contrast | None | |
| PET | 18F-FDG | 555 MBq (15 mCi) | >12 h |
| 11C-choline | 370–740 MBq (10–20 mCi) | >2 h | |
| 13N-ammonia | 370–740 MBq (10–20 mCi) | >1 h | |
| Nuclear medicine | 99mTc-sestamibi for parathyroid or cardiac studies | 370–1,110 MBq (10–30 mCi) | None* |
| 99mTc-radiopharmaceuticals, intravenous | >740 MBq (20 mCi) | >24 h | |
| >370 MBq (10 mCi) | >18 h | ||
| >185 MBq (5 mCi) | >12 h | ||
| <185 MBq (5 mCi) | >6 h | ||
| 99mTc-radiopharmaceuticals, oral | <185 MBq (5 mCi) | None | |
| 123I-based radiopharmaceuticals | >370 MBq (10 mCi) | >2 d | |
| 111In- and 67Ga-based radiopharmaceuticals | 185–370 MBq (5–10 mCi) | >3 d | |
| <37 MBq (1 mCi) | >24 h |
These are general guidelines and in some cases may overestimate waiting period needed, depending on biologic distribution of radiopharmaceutical.
↵* In cases of prior administration of 99mTc-sestamibi for cardiac or parathyroid studies, reduced (or no dose) of 99mTc-sestamibi may be used, depending on residual activity from prior study.